585055AM8

• Q4 GAAP diluted EPS was $0.96; non-GAAP diluted EPS was $1.55.
• FY26 revenue was $36.364 billion, up 8.4% as reported and 5.8% organic.
• FY26 GAAP diluted EPS was $3.73; non-GAAP diluted EPS was $5.53.
• FY27 guidance: organic revenue growth of 6.75% to 7.25% and non-GAAP diluted EPS of $5.90 to $6.00.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will assume the role of Executive Vice President and President, Neuroscience Portfolio on June 1, 2026.
• Mr. Wall will remain an employee of Medtronic until September 1, 2026, to assist with the transition.
• Mr. Wall will receive severance payments and benefits consistent with Medtronic's executive officer severance practices as described in the 2025 Proxy Statement.
• The announcement was made on May 18, 2026.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits

• The company activated incident response protocols and engaged external cybersecurity experts to investigate and remediate.
• Medtronic has not identified any impact to products, patient safety, customer connections, manufacturing, distribution, or financial reporting systems.
• The company does not currently expect the incident to have a material impact on its business or financial results.
• A statement regarding the matter was issued on Medtronic's website and furnished as Exhibit 99.1.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Blackstone Life Sciences Advisors L.L.C. affiliates funded part of the MiniMed Flex R&D; in exchange, Blackstone will earn the greater of a mid-to-high single digit royalty on applicable net sales or specified minimum payments during the first two years after U.S. regulatory approval and commercial launch.
• MiniMed expects a one-time charge of $157 million in Q4 FY2026 related to future payments to Blackstone, resulting in an $0.08 per share impact to Medtronic's consolidated results based on its 90% ownership interest.
• The March 9, 2026 IPO of 10% of MiniMed is expected to cause dilution of approximately $0.02 per share per month, totaling $0.04 per share in Q4 FY2026.
• On March 24, 2026, Medtronic revised its FY2026 non-GAAP EPS guidance to $5.50-$5.54, down from $5.62-$5.66, while FY2027 high single-digit EPS growth guidance remains unchanged.

7.01 Regulation FD Disclosure

• Q3 FY26 revenue was $9.017 billion, an increase of 8.7% as reported and 6.0% on an organic basis.
• Cardiovascular portfolio revenue grew 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolio.
• Company reiterates FY26 organic revenue growth of approximately 5.5% and diluted non-GAAP EPS guidance of $5.62 to $5.66.
• Secured CE Mark for Sphere-360, U.S. FDA clearance for Hugo robotic-assisted surgery and Stealth AXiS Surgical System.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• GAAP diluted EPS was $1.07, up 8%; non-GAAP diluted EPS was $1.36, up 8%.
• Cardiovascular Portfolio revenue grew 10.8% as reported and 9.3% organic, with Cardiac Ablation Solutions up 71%.
• Company raised FY26 organic revenue growth guidance to approximately 5.5% and non-GAAP EPS guidance to $5.62-$5.66.
• Q2 GAAP operating margin was 18.8%; non-GAAP operating margin was 24.1%, both down 20 basis points.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• His retirement is effective December 2, 2025, and he will join a private equity-held organization.
• Smith will be eligible for retirement treatment of outstanding equity compensation as disclosed in the proxy statement filed August 25, 2025.
• Retirement treatment includes acceleration of unvested stock options and continued vesting of RSUs and PSUs per equity award agreements.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• At the October 16, 2025 Annual General Meeting, Medtronic shareholders elected 12 directors, each to serve until the 2026 Annual General Meeting.
• Shareholders approved, in a non-binding advisory vote, named executive officer compensation.
• Shareholders approved renewals of Board authority to issue shares, opt out of pre-emption rights, and make overseas market purchases of ordinary shares.
• Shareholders approved amendments to the Articles of Association, including Article 177 changes and updated advance notice provisions, effective October 16, 2025.

5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits